At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 15 target
Drug / intervention
autologous adipose derived mesenchymal stem cells +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Versus Cultured Allogeneic Adult Umbilical-cord Derived Mesenchymal Stem Cell Intrathecal Injection for the Treatment of Spinal Cord Injury
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Aug 24, 2021·Updated Apr 17, 2025
In Brief
A Phase 1 clinical trial evaluating autologous adipose derived mesenchymal stem cells and AlloRx for Spinal Cord Injuries. Currently recruiting, targeting 15 participants across 2 sites in 2 countries.
Detailed Summary
This trial will study the safety and efficacy of intrathecal injection of cultured autologous adult adipose derived mesenchymal stem cells versus cultured allogeneic adult umbilical-cord derived mesenchymal stem cells for the treatment of spinal cord injury
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Injuries
CountriesAntigua and Barbuda, Greece
Collaborators--
Timeline
Phase 1Recruiting
20222023202420252026202720282029
First PostedAug 2021
Enrollment StartDec 2024
TodayJul 2026
Primary CompletionDec 2028
First PostedAug 24, 2021
Enrollment StartDec 1, 2024
Primary CompletionDec 1, 2028
TodayJul 1, 2026
Enrollment to primary: 4 yearsPosted 4.9 years agoPrimary completion in 2.4 years
Interventions
autologous adipose derived mesenchymal stem cellsbiological
cultured autologous adult adipose derived mesenchymal stem cells
AlloRxbiological
Cultured Allogeneic Adult Umbilical-cord Derived Mesenchymal Stem Cell Intrathecal injection for